Sulindac and Epirubicin in Treating Patients With Metastatic Malignant Melanoma

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

May 31, 2010

Study Completion Date

May 31, 2010

Conditions
Melanoma (Skin)
Interventions
DRUG

epirubicin hydrochloride

DRUG

sulindac

OTHER

immunologic technique

Trial Locations (10)

4

St. Vincent's University Hospital, Dublin

7

Mater Misericordiae University Hospital, Dublin

8

St. James's Hospital, Dublin

9

Beaumont Hospital, Dublin

National Institute for Cellular Biotechnology at Dublin City University, Dublin

24

Adelaide and Meath Hospital, Dublin Incorporating the National Children's Hospital, Dublin

Unknown

Cork University Hospital, Cork

Galway University Hospital, Galway

Waterford Regional Hospital, Waterford

0009

Mid-Western Cancer Centre at Mid-Western Regional Hospital, Limerick

All Listed Sponsors
lead

Cancer Trials Ireland

NETWORK

NCT00755976 - Sulindac and Epirubicin in Treating Patients With Metastatic Malignant Melanoma | Biotech Hunter | Biotech Hunter